Vermillion (NASDAQ:VRML) will report earnings after markets close on Wednesday, May 15th. Vermillion, Inc. discovers, develops, and commercializes diagnostic tests. The Company focuses in the areas of oncology, hematology, cardiology, and women’s health.
Here is your Cheat Sheet to Vermillion Earnings:
Earnings Expectations: Analysts expect earnings of $-0.15 per share on revenues of $300.00K.
Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.18 to a loss $0.15. For the current year, the average estimate is a loss of $0.57, which is better than the estimate ninety days ago.
Here’s how Vermillion has been performing on an annual basis:
|Revenue ($) in millions||0.12||0.00||1.18||1.92||2.09|
|Diluted EPS ($)||-2.87||-3.31||-1.83||-1.25||-0.48|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||0.87||0.31||0.32||0.32||1.14|
|Diluted EPS ($)||-0.2108||-0.12||-0.13||-0.13||-0.0909|
Vermillion has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)